Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensovibep in ambulatory COVID-19 patients
NCT04828161Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Carrier/Scaffold Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of ensovibep in coronavirus disease 2019 (COVID-19), sponsored by Novartis. Started May 2021; status: terminated.
02
Drugs
ensovibep
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04828161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828161.